Related Experiment Video

Updated: Jul 14, 2026

Laparoscopic Choledochal Cyst Excision and Roux-en-Y Choledochojejunostomy in Adults
04:14

Laparoscopic Choledochal Cyst Excision and Roux-en-Y Choledochojejunostomy in Adults

Published on: February 28, 2025

[Vronchiolitis and its treatment]

Georges de Bilderling1

  • 1Service de pédiatrie Cliniques UCL Mont-Godinne. georges.debilderling@pedi.ucl.ac.be

Journal De Pharmacie De Belgique
|May 19, 2007
PubMed

Insights

Bronchiolitis, a common infant illness caused by RSV, leads to high healthcare costs due to frequent hospitalizations and unproven treatments. Evidence-based guidelines can lower costs but don't improve parental satisfaction or care quality.

Area of Science:

  • Pediatrics
  • Infectious Diseases
  • Respiratory Medicine

Context:

  • Bronchiolitis is the most frequent lower respiratory tract infection in infants.
  • Respiratory Syncytial Virus (RSV) is the primary causative agent.
  • High hospitalization rates and treatments with unproven efficacy contribute to significant public health costs.

Purpose:

  • To evaluate the impact of evidence-based guidelines on bronchiolitis management.
  • To assess the effectiveness of Palivizumab as a preventive measure.
  • To explore interventions for post-bronchiolitis bronchial hyperreactivity.

Summary:

  • Evidence-based guidelines can reduce healthcare costs associated with bronchiolitis but do not enhance parental satisfaction or care quality.
  • Palivizumab is a preventive medication with specific indications for certain infants.
  • Post-bronchiolitis bronchial hyperreactivity is observed, especially after hospitalization, with no proven effective treatments currently available.

Impact:

  • Implementation of guidelines can optimize resource allocation in pediatric respiratory care.
  • Understanding Palivizumab's role aids in targeted preventive strategies.
  • Further research is needed to identify effective treatments for post-bronchiolitis bronchial hyperreactivity to improve long-term infant respiratory health.

Related Concept Videos

Chronic Bowel Disorders: Introduction01:17

Chronic Bowel Disorders: Introduction

Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Cholecystitis01:20

Cholecystitis

Cholecystitis is inflammation of the gallbladder, most commonly caused by obstruction of the cystic duct. This blockage prevents bile from draining, leading to gallbladder distension, inflammation, and potentially serious complications. This condition may present acutely or chronically and can happen with or without gallstones.EtiologyAbout 95% of cholecystitis cases are calculous, caused by gallstones blocking the cystic duct, leading to bile accumulation and inflammation of the gallbladder...
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Tonsillitis II: Management01:26

Tonsillitis II: Management

This lesson will focus on the different treatment options for managing tonsillitis, which typically depend on the cause and severity.
Gastritis III: Clinical Manifestations and Management01:23

Gastritis III: Clinical Manifestations and Management

The clinical manifestations of gastritis can vary depending on the cause and type of gastritis, but some common symptoms may include the following.
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...